Federal Circuit: First-Filed, First-Issued Patent Sets the Term for Obviousness-Type Double Patenting Analysis Even When Granted PTA

August 13, 2024

Reading Time : 2 min

In a case it described as “‘a prime example’ of when ODP does not apply,” the Federal Circuit recently reversed a decision from the District of Delaware that invalidated a claim for obviousness-type double patenting (ODP), holding that a first-filed, first-issued, later-expiring claim cannot be invalidated for ODP based on a later-filed, later-issued, but earlier-expiring claim from the same family. In so doing, the court answered the question of whether a later-filed, later-issued patent in the same family can be an ODP reference against the first application in the family—it cannot. The court also clarified the scope of its prior ruling in In re Cellect, explaining that case answered a different question—the question of what expiration date should be used for an ODP analysis.

In this case, Allergan sued Sun Pharmaceuticals under the Hatch-Waxman Act after Sun submitted an Abbreviated New Drug Application (ANDA) to market a generic version of the drug Viberzi. One of the asserted patents, U.S. Patent No. 7,741,356 (“the ’356 patent”), had been granted 4671 days of patent term adjustment (PTA) for delays during its prosecution. As a result and as shown in the diagram below, the ’356 patent had an expiration date that was 467 days later than two later-filed and later-issued patents in the same family.

 

                                                           

In the district court, Sun challenged the validity of claim 40 of the ’356 patent on ODP grounds, relying on the later-filed, later-issued patents as reference patents. Specifically, Sun argued that because the claims of the three patents are not patentably distinct and because claim 40 of the ’356 patent has a later expiration date, it must be invalid for ODP. The district court agreed with Sun and found claim 40 invalid based solely on its later expiration date.

On appeal, Allergan argued that the district court misunderstood Cellect, contending that this case presented a different scenario. According to Allergan, because the ’356 patent was the first patent to be filed and first patent to issue in the family, it is not subject to ODP challenges over the later-filed, later-issued patents. And consequently, the rule of Cellect simply does not apply.

The Federal Circuit agreed with Allergan, explaining that Cellect established a rule whereby PTA is included in the expiration date when conducting an ODP analysis. Cellect did not, however, define the circumstances under which a patent can properly serve as an ODP reference. In particular, Cellect did not consider whether a first-filed, first-issued patent that receives PTA can be invalidated for ODP based on a later-filed patent with the same priority date. As to that question, the Federal Circuit held in this case that it cannot. To rule otherwise, would be “antithetical to the principles of ODP,” which serves to prevent a patentee from obtaining a second later-expiring patent directed to patentably indistinct subject matter. Thus, where the later-expiring patent is the first patent in the family to be filed and the first patent in the family to issue, PTA does not extend the period of exclusivity—it sets the term.

Allergan USA, Inc. v. MSN Laboratories Private Ltd., C.A. No. 2024-1061 (August 13, 2024)


1The USPTO initially awarded 1,107 days of PTA to the ’356 patent, but all but 467 days were disclaimed as part of an application for patent term extension (PTE).

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.